文献速递心力衰竭与心肌病

Titin截短变异型扩张型心肌病的表型与临床结局

Phenotype and Clinical Outcomes of Titin Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

这项前瞻性观察队列研究纳入716例扩张型心肌病患者,83例(11.6%)携带TTNtv。TTNtv阳性患者更年轻且左室质量指数更低,但双心室射血分数无差异;中位随访3.9年,TTNtv阳性与阴性患者的主要复合终点(心血管死亡、主要心律失常和心衰事件)无显著差异(校正HR 0.92,95%CI 0.45-1.87,P=0.82)。

要点

  • TTNtv在扩张型心肌病患者中占11.6%,阳性者更年轻且左室质量更低。
  • TTNtv阳性与阴性患者双心室射血分数无差异。
  • TTNtv阳性不增加中期主要心血管事件风险(校正HR 0.92)。

核心结论

  • 在门诊扩张型心肌病患者中,TTNtv与更差的中期预后无关。
  • 全因DCM的预后因素同样适用于TTNtv型DCM。

研究设计与样本

  • 前瞻性观察队列研究,纳入716例DCM患者,行临床评估、LGE-CMR、TTN测序及盲法结局判定。
  • 平均年龄53.5±14.3岁,男性469例(65.5%),NYHA I/II级577例(80.6%)。

主要发现

  • 83例(11.6%)携带TTNtv,TTNtv阳性者入组年龄更轻(49.0岁 vs 54.1岁,P=0.002)。
  • TTNtv阳性者左室质量指数更低(降低5.1 g/m2,校正P=0.03)。
  • 双心室射血分数在TTNtv阳性与阴性组间无差异。
  • 604例中78例(12.9%)达到主要终点,TTNtv阳性9/71(12.7%),阴性69/533(12.9%)。
  • 主要复合终点校正HR 0.92(95%CI 0.45-1.87,P=0.82),中位随访3.9年(IQR 2.0-5.8年)。

临床怎么用

  • TTNtv检测可辅助DCM病因分型,但不应据此判断中期预后更差。
  • TTNtv阳性DCM患者的管理可参照一般DCM的预后因素进行风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Improved understanding of dilated cardiomyopathy (DCM) due to titin truncation (TTNtv) may help guide patient stratification. OBJECTIVES: The purpose of this study was to establish relationships among TTNtv genotype, cardiac phenotype, and outcomes in DCM. METHODS: In this prospective, observational cohort study, DCM patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic resonance, TTN sequencing, and adjudicated follow-up blinded to genotype for the primary composite endpoint of cardiovascular death, and major arrhythmic and major heart failure events. RESULTS: Of 716 subjects recruited (mean age 53.5 ± 14.3 years; 469 men [65.5%]; 577 [80.6%] New York Heart Association function class I/II), 83 (11.6%) had TTNtv. Patients with TTNtv were younger at enrollment (49.0 years vs. 54.1 years; p = 0.002) and had lower indexed left ventricular mass (5.1 g/m2 reduction; padjusted = 0.03) compared with patients without TTNtv. There was no difference in biventricular ejection fraction between TTNtv+/- groups. Overall, 78 of 604 patients (12.9%) met the primary endpoint (median follow-up 3.9 years; interquartile range: 2.0 to 5.8 years), including 9 of 71 patients with TTNtv (12.7%) and 69 of 533 (12.9%) without. There was no difference in the composite primary outcome of cardiovascular death, heart failure, or arrhythmic events, for patients with or without TTNtv (hazard ratio adjusted for primary endpoint: 0.92 [95% confidence interval: 0.45 to 1.87]; p = 0.82). CONCLUSIONS: In this large, prospective, genotype-phenotype study of ambulatory DCM patients, we show that prognostic factors for all-cause DCM also predict outcome in TTNtv DCM, and that TTNtv DCM does not appear to be associated with worse medium-term prognosis.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Tayal U, Newsome S, Buchan R, et al. Phenotype and Clinical Outcomes of Titin Cardiomyopathy. J Am Coll Cardiol. 2017. PMID: 29073955. doi:10.1016/j.jacc.2017.08.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。